Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Company Overview - Cidara Therapeutics is a biotechnology company utilizing its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies [3] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [3] - Cidara is headquartered in San Diego, California [3] Recent Developments - Cidara will participate in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025, at 11:00 AM ET [1] - The company has completed enrollment of its 5000 patient Phase 2b NAVIGATE trial for CD388 in December 2024 [3] - Cidara received Fast Track Designation from the U.S. FDA for CD388 in June 2023 [3] - In July 2024, Cidara received IND clearance for CBO421, targeting CD73 in solid tumors [3] Investor Engagement - Cidara will engage in one-on-one investor meetings during the Needham conference [2] - Investors interested in meetings should contact their Needham representative directly [2]